use [ftcn]    
5-alpha Reductase Inhibitor [moft]    
Not [ftcn]    
Increase [ftcn]    
Risk [qlco]    
Cardiovascular disease [dsyn]    
patient [podg]    
benign prostate hyperplasia [patf]    
Five [qnco]    
year [tmco]    
Follow-Up Studies [resa]    
Background [cnce]    
thi [euka]    
Population [qnco]    
base [ftcn]    
investigate [ftcn]    
Risk [qlco]    
Cardiovascular disease [dsyn]    
5-alpha Reductase Inhibitor [phsu]    
Therapies [ftcn]    
benign prostate hyperplasia [patf]    
Using [ftcn]    
National Health Insurance [hlca]    
research [resa]    
Database [inpr]    
Taiwan [geoa]    
Method [inpr]    
% total [qnco]    
1+ [qnco]    
Adult [aggp]    
patient [podg]    
newly [idcn]    
diagnose [fndg]    
benign prostate hyperplasia [patf]    
used [fndg]    
5-alpha Reductase Inhibitor [moft]    
studies [mnob]    
Cohort [popg]    
Subject [grup]    
Not [ftcn]    
use [ftcn]    
5-alpha Reductase Inhibitor [moft]    
Comparison [acty]    
Cohort [popg]    
*^patient [podg]    
monitor [hlca]    
>5 [qnco]    
year [tmco]    
Cardiovascular disease [dsyn]    
Identifiable [qlco]    
used [fndg]    
To [qlco]    
Compare [acty]    
Risk [qlco]    
Cardiovascular disease [dsyn]    
studies [mnob]    
Comparison [acty]    
Cohort [popg]    
Possible [qlco]    
Risk factor [qnco]    
Result [ftcn]    
patient [podg]    
Receive [qlco]    
5-alpha Reductase Inhibitor [phsu]    
Therapies [ftcn]    
Lower [spco]    
Cumulative [qlco]    
Rate [acty]    
Cardiovascular disease [dsyn]    
Not [ftcn]    
Receive [qlco]    
5-alpha Reductase Inhibitor [phsu]    
Therapies [ftcn]    
>5 [qnco]    
year [tmco]    
Follow-up [fndg]    
period [tmco]    
subgroup [virs]    
Analysis [lbpr]    
>5 [qnco]    
year [tmco]    
Cardiovascular event [fndg]    
Hazard Ratio [qnco]    
Lower [spco]    
patient [podg]    
Old [tmco]    
65 [inpr]    
year [tmco]    
Cumulative Dose [cnce]    
Defined [cnce]    
Daily [tmco]    
5-alpha Reductase Inhibitor [phsu]    
use [ftcn]    
Hazard Ratio [qnco]    
Confidence Interval [qnco]    
0.018" [qnco]    
*Difference [qnco]    
patient [podg]    
>90 [qnco]    
More [ftcn]    
Cumulative Dose [cnce]    
Defined [cnce]    
Daily [tmco]    
5-alpha Reductase Inhibitor [phsu]    
use [ftcn]    
Hazard Ratio [qnco]    
1+ [qnco]    
Confidence Interval [qnco]    
1+ [qnco]    
68 [inpr]    
Hazard Ratio [qnco]    
Confidence Interval [qnco]    
1+ [qnco]    
Conclusion [idcn]    
5-alpha Reductase Inhibitor [phsu]    
Therapies [ftcn]    
Not [ftcn]    
Increase [ftcn]    
Risk [qlco]    
Cardiovascular event [fndg]    
benign prostate hyperplasia [patf]    
patient [podg]    
>5 [qnco]    
year [tmco]    
Follow-up [fndg]    
Further [spco]    
Mechanical [ftcn]    
research [resa]    
Needed [qlco]    
